MedTrace Logo

Single Ascending Dose Study of TRN-157 in Healthy Subjects

NCT02133339 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-10-31

No results posted yet for this study

Summary

This single ascending dose study is to determine and evaluate the safety and tolerability of TRN-157 in approximately 40 healthy subjects.

Conditions

Interventions

DRUG

TRN-157

DRUG

Placebo

Sponsors & Collaborators

  • Theron Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Joe Oren · Theron Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2014-08-31
Completion
2014-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02133339 on ClinicalTrials.gov